A single-institute phase I/II trial combining nedaplatin dose escalation with a fixed dose of docetaxel for induction chemotherapy of oral squamous cell carcinoma

Oral Oncology

Volumn 44, Issue 5, 2008, Pages 471-476

  Miyazaki, Akihiro ^a   Kobayashi, Junichi ^a   Yamamoto, Takashi ^a   Kido, Yukie ^a   Takemura, Kanako ^a   Abe, Masato ^a   Tomihara, Kei ^a   Dehari, Hironari ^a   Nakamori, Kenji ^a   Nagai, Itaru ^a   Hiratsuka, Hiroyoshi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Docetaxel; Dose escalation; Induction chemotherapy; Nedaplatin; Oral squamous cell carcinoma; Phase I; Phase II

Indexed keywords

DEXAMETHASONE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; NEDAPLATIN; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MOUTH CARCINOMA; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MOUTH NEOPLASMS; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; REMISSION INDUCTION; TAXOIDS;

EID: 42949169552     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2007.06.005     Document Type: Article

References (22)

1. Paccagella A., Orlando A., Marchiori C., Zorat P.L., Cavaniglia G., Sileni V.C., et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers. A study by the Gruppo di Studio sui tumori della Testa e del Collo. J Natl Cancer Inst 86 (1994) 265-722
2. Colevas A.D., Norris C.M., Tishler R.B., Fried M.P., Gomolin H.I., Amrein P., et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction foe squamous cell carcinoma of the head and neck. J Clin Oncol 17 (1999) 3503-3511
3. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324 (1991) 1685-1690
4. Clayman G.L., Weber R.S., Guillamondegui O., Byers R.M., Wolf P.F., Frankenthaler R.A., et al. Laryngeal preservation for advanced laryngeal and hypopharyngeal cancers. Arch Otolaryngol Head Neck Surg 121 (1995) 219-223
5. Catimel G., Verweij J., Mattijssen V., Hanauske A., Piccart M., Wanders J., et al. Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5 (1994) 533-537
6. Couteau C., Chouaki N., Leyvraz S., Oulid-Aissa D., Lebecq A., Domenge C., et al. A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer 81 (1999) 457-462
7. Inuyama Y., Kataura A., Togawa K., Saijo S., Satake B., Takeoda S., et al. Late phase II clinical study of RP56976 (Docetaxel) in patients with advanced/recurrent head and neck cancer. Jpn J Cancer Chemother 26 (1999) 107-116
8. Dreyfuss A.I., Clark J.R., Norris C.M., Rossi R.M., Lucarini J.W., Busse P.M., et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14 (1996) 1672-1678
9. Ringel I., and Horwitz S.B. Studies with RP56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 83 (1991) 288-291
10. Inuyama Y., Miyake H., Horiuchi M., Hayasaki K., Komiyama K., and Ota K. A late phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers. Jpn J Cancer Chemother 19 (1992) 871-877
11. Inuyama Y., Miyake H., Horiuchi M., Hayasaki K., Komiyama K., and Ota K. An early phase II study of cis-diammine glycolato platinum, 254-S, for head and neck cancers. Jpn J Cancer Chemother 19 (1992) 863-869
12. Taguchi T., Wakui A., Nabeya K., Kurihara M., Isono K., Kakegawa T., et al. A phase II clinical study of cis-diammine glycolate platinum, 254-S, for gastrointestinal cancers. Jpn J Cancer Chemother 19 (1992) 483-488
13. Noda K., Ikeda M., Yakushiji M., Nishimura H., Terashima Y., Sasaki H., et al. A phase II clinical study of cis-diammine glycolate platinum, 254-S, for cervical cancer of the uterus. Jpn J Cancer Chemother 19 (1992) 885-892
14. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 (1982) 649-655
15. Lowitz B.B., and Casciato D.A. Principles of medical oncology and cancer biopsy. In: Casiato D.A., and Lowitz B.B. (Eds). Manual of clinical oncology. 4th ed. (2000), Lippincott Williams and Wilkins, Philadelphia 3-28
16. Shimosato Y., Oboshi S., and Baba K. Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas. Jpn J Clin Oncol 1 (1971) 19-35
17. Kato T., Nishimura H., Yakushiji M., Noda K., Terashima Y., Takeuchi S., et al. Phase II study of 254-S(cis-diammine glycolato platinum) for gynecological cancer. Jpn J Cancer Chemother 19 (1992) 695-701
18. Kurita H., Yamamoto E., Nozaki S., Wada S., Furuta I., and Kurashina K. Multicenter phase I trial of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma. Oral Oncol 40 (2004) 1000-1006
19. Calvert A.H. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel. Semin Oncol 24 (1997) S2-85-S2-90
20. de Graff M., Maliepaaid M., Pluim D., JG Floot B., CM Slaper-Cortenbach I., and HM Schellens J. In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM. Anti-Cancer Drug 10 (1999) 213-218
21. Yamada H., Maki H., Takeda Y., and Orita S. Evaluation of combined nedaplatin and docetaxel therapy for human head and neck cancer in vivo. Anticancer Res 26 (2006) 989-994
22. Ryo K., Isobe K., Toyama K., Sugino K., Sano G., Yamada H., et al. The platelet-sparing effect of carboplatin and docetaxel combination chemotherapy for lung cancer. Jpn J Cancer Chemother 30 (2003) 1435-1439